Фактори ризику тромбозу глибоких вен та тромбоемболії легеневої артерії

Age > 60 years

Cancer and myeloproliferative neoplasms

Certain chemotherapeutic agents (eg, bevacizumab, thalidomide)

Hormonal modulation

• Estrogen receptor modulators (eg, raloxifene, tamoxifen)

• Exogenous estrogens and progestins, including oral contraceptives and estrogen therapy

• Exogenous testosterone

Heart failure

Immobilization/reduced mobility (eg, prolonged car rides, air travel)

Indwelling venous catheters

Infection (ie, as a cause of immobility and systemic inflammatory response; SARS-CoV-2 appears prothrombotic)

Nephrotic syndrome

Obesity

Pregnancy/postpartum period

Prior thromboembolism

Sickle cell disease

Smoking

Stroke

Thrombotic disorders (thrombophilias)

• Antiphospholipid syndrome

• Antithrombin deficiency

• Factor V Leiden mutation (activated protein C resistance)

• Heparin-induced thrombocytopenia

• Hereditary fibrinolytic defects

• Hyperhomocystinemia

• Increase in factor VIII levels

• Increase in factor XI levels

• Increase in von Willebrand factor levels

• Paroxysmal nocturnal hemoglobinuria

• Protein C deficiency

• Protein S deficiency

• Prothrombin G20210A gene variant

• Tissue factor pathway inhibitor deficiency or impaired function

Trauma/surgery

Other conditions associated with reduced mobility, venous injury, or hypercoagulability